The challenge

Snakebite envenoming causes an estimated 140,000 deaths each year and leaves over 400,000 survivors with permanent disabilities. The burden is highest in rural, low-income communities in sub-Saharan Africa, South and Southeast Asia, and South and Central America, where they are far from timely care or effective treatment.

Treatments are often expensive, and health systems lack the resources, data, and infrastructure needed to respond effectively. Preventable deaths persist, and progress is held back by scientific, logistical, and systemic barriers.

About the project

ANYSNAKES (Assessing New and Existing Snakebite Antivenoms for Safety and Efficacy) is a large-scale, randomised clinical trial led by the Centre for Snakebite Research and Interventions (CSRI) at LSTM.

The project aims to evaluate and compare the safety and effectiveness of different antivenoms used to treat snakebite envenoming. By conducting the trial across multiple countries in sub-Saharan Africa, ANYSNAKES aims to provide robust data on the performance of these treatments in real-world settings.

Our strategies & approaches

Comparative evaluation

The trial focuses on assessing how different antivenoms improve blood clotting and reduce other signs of severe snakebite. This includes measuring the level of antivenom in each patient’s blood and comparing it to the venom from the snakebite.

Safety monitoring

We monitor the frequency of allergic reactions and problems with the brain and central nervous system associated with the use of antivenoms. This helps us determine the most appropriate dose of each antivenom and compare them with each other.

Real-world testing

By conducting the trial in multiple centres across sub-Saharan Africa, the study ensures that findings are applicable to the regions most affected by snakebite envenoming.

Our planned impact 

Evidence-based recommendations

The data collected will inform guidelines on the most effective and safe antivenoms, leading to better treatment protocols in regions where snakebite is prevalent.

Improving patient outcomes

By identifying the most effective antivenoms, the trial will help reduce mortality and morbidity associated with snakebite envenoming.

Policy influence

We will share the findings with national health authorities and global partners to influence procurement decisions and policies. This ensures that the most effective antivenoms are available in the regions that need them most.